Intra-Tumor Heterogeneity of Colorectal Cancer Necessitates the Multi-Regional Sequencing for Comprehensive Mutational Profiling

References

• Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–337. doi:10.1038/nature11252.22810696
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–421. doi:10.1038/nature1247723945592
   PubMed Web of Science ®Google Scholar
• Saito T, Niida A, Uchi R, et al. A temporal shift of the evolutionary principle shaping intratumor heterogeneity in colorectal cancer. Nat Commun. 2018;9(1):2884. doi:10.1038/s41467-018-05226-030038269
   PubMed Web of Science ®Google Scholar
• Punt CJ, Koopman M, Vermeulen L. From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol. 2017;14(4):235–246. doi:10.1038/nrclinonc.2016.17127922044
   PubMed Web of Science ®Google Scholar
• Uchi R, Takahashi Y, Niida A, et al. Integrated multiregional analysis proposing a new model of colorectal cancer evolution. PLoS Genet. 2016;12(2):e1005778. doi:10.1371/journal.pgen.100577826890883
   PubMed Web of Science ®Google Scholar
• Bramsen JB, Rasmussen MH, Ongen H, et al. Molecular-subtype-specific biomarkers improve prediction of prognosis in colorectal cancer. Cell Rep. 2017;19(6):1268–1280. doi:10.1016/j.celrep.2017.04.04528494874
   PubMed Web of Science ®Google Scholar
• Phipps AI, Limburg PJ, Baron JA, et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology. 2015;148(1):77–87.e2. doi:10.1053/j.gastro.2014.09.03825280443
   PubMed Web of Science ®Google Scholar
• Cao H, Liu X, Chen Y, et al. Circulating tumor DNA is capable of monitoring the therapeutic response and resistance in advanced colorectal cancer patients undergoing combined target and chemotherapy. Front Oncol. 2020;10:466.32318348
   PubMed Web of Science ®Google Scholar
• Kyrochristos ID, Roukos DH. Comprehensive intra-individual genomic and transcriptional heterogeneity: evidence-based Colorectal Cancer Precision Medicine. Cancer Treat Rev. 2019;80:101894. doi:10.1016/j.ctrv.2019.10189431518831
   PubMed Web of Science ®Google Scholar
• Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? Genet Med. 2013;15(7):517–527. doi:10.1038/gim.2012.184.23429431
   PubMed Web of Science ®Google Scholar
• Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol. 2014;53(7):852–864. doi:10.3109/0284186X.2014.89503624666267
   PubMed Web of Science ®Google Scholar
• De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753–762. doi:10.1016/S1470-2045(10)70130-320619739
   PubMed Web of Science ®Google Scholar
• Schrock AB, Ouyang C, Sandhu J, et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol. 2019;30(7):1096–1103. doi:10.1093/annonc/mdz13431038663
   PubMed Web of Science ®Google Scholar
• Parikh AR, He Y, Hong TS, et al. Analysis of DNA damage response gene alterations and tumor mutational burden across 17,486 tubular gastrointestinal carcinomas: implications for therapy. Oncologist. 2019;24(10):1340–1347. doi:10.1634/theoncologist.2019-003431040255
   PubMed Web of Science ®Google Scholar
• Picard E, Verschoor CP, Ma GW, Pawelec G. Relationships between immune landscapes, genetic subtypes and responses to immunotherapy in colorectal cancer. Front Immunol. 2020;11:369. doi:10.3389/fimmu.2020.0036932210966
   PubMed Web of Science ®Google Scholar
• Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26(4):566–576. doi:10.1038/s41591-020-0805-832251400
   PubMed Web of Science ®Google Scholar
• Cohen R, Shi Q, André T. Immunotherapy for early stage colorectal cancer: a glance into the future. Cancers (Basel). 2020;12(7):1990. doi:10.3390/cancers12071990
   PubMed Web of Science ®Google Scholar
• Sottoriva A, Kang H, Ma Z, et al. A Big Bang model of human colorectal tumor growth. Nat Genet. 2015;47(3):209–216. doi:10.1038/ng.321425665006
   PubMed Web of Science ®Google Scholar
• Graham TA, Sottoriva A. Measuring cancer evolution from the genome. J Pathol. 2017;241(2):183–191. doi:10.1002/path.482127741350
   PubMed Web of Science ®Google Scholar
• Normanno N, Rachiglio AM, Lambiase M, et al. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. Ann Oncol. 2015;26(8):1710–1714. doi:10.1093/annonc/mdv17625851630
   PubMed Web of Science ®Google Scholar
• Maron SB, Chase LM, Lomnicki S, et al. Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma. Clin Cancer Res. 2019;25(23):7098–7112. doi:10.1158/1078-0432.CCR-19-170431427281
   PubMed Web of Science ®Google Scholar
• Li G, Pavlick D, Chung JH, et al. Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy. J Gastrointest Oncol. 2019;10(5):831–840. doi:10.21037/jgo.2019.05.0531602320
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chang L, Yang Y, et al. Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing. Mol Cancer. 2019;18(1):7. doi:10.1186/s12943-019-0939-930626401
   PubMed Web of Science ®Google Scholar
• Wu H, Zhang XY, Hu Z, et al. Evolution and heterogeneity of non-hereditary colorectal cancer revealed by single-cell exome sequencing. Oncogene. 2017;36(20):2857–2867. doi:10.1038/onc.2016.43827941887
   PubMed Web of Science ®Google Scholar
• Liu M, Liu Y, Di J, et al. Multi-region and single-cell sequencing reveal variable genomic heterogeneity in rectal cancer. BMC Cancer. 2017;17(1):787. doi:10.1186/s12885-017-3777-429169336
   PubMed Web of Science ®Google Scholar